Investment Analysts’ Weekly Ratings Changes for GRAIL (GRAL)

GRAIL (NASDAQ: GRAL) has recently received a number of price target changes and ratings updates:

• 5/9/2026 – GRAIL was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – GRAIL had its price target raised by TD Cowen from $65.00 to $69.00. They now have a “buy” rating on the stock.
• 5/6/2026 – GRAIL had its price target raised by Piper Sandler from $54.00 to $56.00. They now have a “neutral” rating on the stock.
• 5/6/2026 – GRAIL was given a new $70.00 price target by Robert W. Baird.
• 4/21/2026 – GRAIL had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/11/2026 – GRAIL was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/10/2026 – GRAIL is now covered by Piper Sandler. They set a “neutral” rating and a $54.00 price target on the stock.
• 4/10/2026 – GRAIL is now covered by Mizuho. They set a “neutral” rating and a $58.00 price target on the stock.
• 3/30/2026 – GRAIL had its price target lowered by Guggenheim from $130.00 to $75.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In related news, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer directly owned 260,669 shares of the company’s stock, valued at approximately $13,012,596.48. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 310,267 shares of company stock valued at $15,485,396. Insiders own 1.83% of the company’s stock.

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.